> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-31/
- Published: 2021-02-15T12:00:00.000Z
- Updated: 2026-09-14T16:46:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148675

**Joint Panel to Review Pfizer Osteoarthritis BLA**  
*Federal Register* notice: FDA has announced a 3/24 joint meeting of the Arthritis and the Drug Safety and Risk Management Advisory Committees. Panel members are scheduled to discuss a Pfizer BLA for tanezumab subcutaneous injection, indicated for relieving signs and symptoms of moderate to severe osteoarthritis in adult patients for whom use of other analgesics is ineffective or not appropriate. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-02-16/pdf/2021-03068.pdf?ref=fdaweb.com). 2/12/2021  

**Final Guide Revised on Convalescent Plasma**  
FDA has issued a revised [final guidance](https://www.fda.gov/media/136798/download?ref=fdaweb.com) entitled “Investigational Covid-19 Convalescent Plasma.” The agency has revised the recommendations in the guidance addressing convalescent plasma donors. The revisions discuss when individuals who have received an investigational Covid-19 monoclonal antibody therapy as a participant in a clinical trial, or received an authorized or licensed Covid-19 monoclonal antibody therapy, qualify as convalescent plasma donors. It also revises the recommendations in the guidance pertaining to the qualification and labeling of high titer Covid-19 convalescent plasma under an EUA. 2/12/2021  

**Info Collection Revision on New Drug Applications**  
*Federal Register* notice: FDA has submitted to OMB an information collection revision entitled “Application for FDA Approval To Market a New Drug” (OMB Control No. 0910-0001). The revision pertains to provisions established through the agency’s user fee programs, most recently authorized under the FDA Reauthorization Act of 2017\. These provisions relate to review transparency, communications with FDA, dispute resolution, drug safety enhancements, and agency resource allocation to align with program objectives agreed upon during user fee negotiations (e.g., “Performance Goals for Fiscal Years 2018-2022” Commitment Letters). To view the notice, click [here](https://public-inspection.federalregister.gov/2021-03023.pdf?ref=fdaweb.com). 2/12/2021